Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.54%
#4 aPriori aPriori +175.89%
#5 Bedrock Bedrock +77.61%
#6 Cysic Cysic +53.64%
#7 Prom Prom +47.31%
#8 Playnance Playnance +34.87%
#9 Bitway Bitway +28.74%
#10 COTI COTI +27.09%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Rosetta Genomics Ltd. Rosetta Genomics Ltd.

Rosetta Genomics Ltd.

ROSGQ
Rank in Stocks #42629
Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics.... Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics. The company leverages its proprietary microRNA technologies to offer a range of diagnostic assays, including RosettaGX Cancer Origin, which helps pinpoint the primary source of metastatic cancer; mi-KIDNEY, designed for classifying kidney tumors from pathological specimens; RosettaGX Reveal, used to interpret indeterminate thyroid fine-needle aspirate results; and various mi-LUNG diagnostic tests. In addition to its microRNA-based portfolio, Rosetta Genomics provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay. This assay serves as an adjunct to, rather than a substitute for, conventional diagnostic methods, aiding in the initial detection of bladder carcinoma in patients with hematuria and in the ongoing surveillance for tumor recurrence in those previously diagnosed with bladder cancer. The company also offers ERG/PTEN, which are FISH-based tests providing prognostic information for prostate cancer. Furthermore, Rosetta Genomics supplies ALK/ROS1, a set of FISH-based predictive tests specifically intended for individuals with late-stage lung cancer, along with PCR gene mutation analysis for patients with bladder, lung, colon, and melanoma cancers. Its diagnostic solutions are utilized by a diverse group of medical professionals, including oncologists, urologists, endocrinologists, and cytopathologists, empowering them to deliver improved patient care. The company holds a licensing agreement with Max Planck Innovation GmbH, securing rights to its patented microRNA technologies for both diagnostic applications and research initiatives. Moreover, Rosetta Genomics has entered into a collaborative partnership with Meir Medical Center to develop a microRNA classifier, focusing on non-small cell lung cancer patients being considered for immuno-oncology therapies. Established in 2000, Rosetta Genomics Ltd. maintains its headquarters in Rehovot, Israel.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$593.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
IL
Trade Rosetta Genomics Ltd. (ROSGQ)

Category

Healthcare
Revenue for Rosetta Genomics Ltd. (ROSGQ)
Revenue in Aug 2026 TTM: 0
According to Rosetta Genomics Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Rosetta Genomics Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 $46.34B -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 $25.11B -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 $4.55B -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 $2.71B -
US